Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis
2019
Recent evidence suggests that renal dysfunction may be a direct consequence of primary
myelofibrosis(PMF). We performed a retrospective analysis of 100 patients with previously untreated PMF, receiving frontline treatment with single agent
ruxolitinib, and compared them to 105 patients, receiving frontline treatment with a non-
ruxolitinib-based therapy, matched by age, sex, DIPSS plus, and estimated glomerular filtration rate (eGFR). Use of
ruxolitinibassociated with a significantly higher rate of renal improvement (RI) > 10% (73% vs 50%, p = 0.01) confirmed on multivariate analysis (MVA) [odds ratio 3, 95% confidence interval (CI) 1.6–5.5, p 10% maintained its independent association with prolonged FFS on MVA (hazard ratio 1.4, 95% CI 1.1–2, p = 0.02).
Ruxolitinibcan significantly improve renal function in patients with PMF, significantly impacting failure-free survival.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
42
References
11
Citations
NaN
KQI